A randomized, parallel-group, double-blind, placebo-controlled, safety and exploratory efficacy and pharmacokinetic study of R04917523 in pediatric patients with Fragile X Syndrome

ID Number 13-0341

Principal Investigator(s)
Alexander Kolevzon

Department(s) or Division(s)


This is a study to examine the efficacy and safety of RO4917523, an experimental oral medication that is an mGlur5 receptor antagonist in subjects aged 5-8 with Fragile X syndrome. All subjects will receive 12 weeks of treatment with RO4917523 or placebo in a double-blind, placebo-controlled, parallel group study design. 

Contact Information
Stacey Lurie
(212) 241-3692

Recruiting Patients: Yes